Demystifying Macrogenics: Insights From 5 Analyst Reviews
Portfolio Pulse from Benzinga Insights
Macrogenics (NASDAQ:MGNX) received mixed reviews from 5 analysts, with recent ratings ranging from bullish to somewhat bullish. The average 12-month price target is $14.00, a significant increase from the previous $10.33. Analysts from JMP Securities, Citigroup, Stifel, HC Wainwright & Co., and Guggenheim have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Macrogenics, a biotech company specializing in antibody-based cancer therapeutics, has a market cap below industry benchmarks and experienced a significant revenue decline of -75.09% over the last quarter. However, it has a high net margin of 168.84%, an ROE of 9.6%, and an ROA of 5.44%, indicating strong profitability and financial management.
January 24, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have updated their ratings and price targets for Macrogenics, indicating a positive outlook with an average price target of $14.00. Despite a recent revenue decline, the company's profitability metrics are strong.
The positive revisions in analyst ratings and price targets suggest optimism about Macrogenics' future performance, which could lead to a short-term increase in stock price. The high net margin, ROE, and ROA are likely to be viewed favorably by investors, despite the recent revenue decline. The confidence score reflects the mixed analyst views and the current financial health indicators.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100